Skip to main content
European Commission logo
Cancer Screening, Diagnosis and Care

European guidelines on breast cancer screening and diagnosis


Select a topic

Breast cancer screening







Select presentation view



Select a topic

Breast cancer diagnosis








Select a profile



2. Screening ages and frequencies


Women aged 40-44: screening vs. no screening

Issued on: June 2016

Healthcare question

Healthcare question

Should organised mammography screening vs. no mammography screening be used for early detection of breast cancer in women aged 40 to 44?

Recommendation

Recommendation

For asymptomatic women aged 40 to 44 with an average risk of breast cancer, the ECIBC's Guidelines Development Group (GDG) suggests not implementing mammography screening.

Recommendation strength

Conditional recommendation
Moderate certainty of the evidence

Justification

Justification

The conditional recommendation (rather than strong) against mammography screening, in the context of an organised screening programme, was the result of a balance of the health effects that probably favours no mammography screening. GDG members agreed that mammography screening has large undesirable effects and small desirable effects when the first screening occurs at age 40.

Subgroup considerations

Subgroup considerations

This recommendation does not apply to high-risk women (see recommendations for women with high breast density).

Considerations for implementation and policy making

Considerations

GDG members agreed on the need for additional imaging techniques in this age group, as well as the need for shared decision making.

Monitoring and evaluation

Monitoring and evaluation

Future monitoring and evaluation of screening services should consider benefits and risks in the context of evolving treatment and management protocols. Monitoring and evaluation criteria are being developed within the ECIBC initiative 

Research priorities

Research priorities
  • Carry out evaluations of the efficacy of the intervention, time intervals, risk factors and stratification of women, as well as context specific cost-effectiveness in this age group.
  • Carry out studies addressing the role of other screening modalities (such as magnetic resonance imaging MRI) in this population.

Supporting material

yes